The partnership allows INC to conduct research work on Debiopharm’s drug development project with the management of a clinical study.
The partnership further agrees that the Debiopharm’s future clinical studies will also be conducted by INC Research.
INC Research’s clinical delivery alliance structures include complete management of a compound or therapeutic area; management of a specific function or set of critical processes as well as risk and reward sharing.
INC Research president Kelvin Logan said their therapeutic expertise along with experience in conducting trials supports Debiopharm’s drug development efforts in bringing medicines to market more quickly and efficiently.